AI Tech / news
OpenAI Acquires Orchestra Bio to Expand Biotech AI Push
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech software startup, to strengthen its life-sciences tools. The deal’s terms were not disclosed; Orchestra’s team and technology will join work on OpenAI’s Rosalind model and Rosalind Workbench.
Orchestra Bio builds AI agents intended to handle operational work for biotech drug discovery, including financial tracking and scheduling issues tied to clinical trials. The startup had reportedly raised about $20 million as of 2025, with Andreessen Horowitz, Atria and 8VC among its backers.
OpenAI announced the acquisition on Tuesday. Financial terms were not disclosed, and the purchase price and other deal conditions remain undisclosed.
OpenAI plans to use Orchestra’s personnel and software in Rosalind, its AI model for life-sciences research, and in Rosalind Workbench, a tool designed to help researchers plan experiments and analyze results.
Rosalind has already attracted large pharmaceutical customers, according to OpenAI, including Moderna and Novo Nordisk. The acquisition extends OpenAI’s move into software tailored for major industries such as pharma.
The deal reflects a broader push by leading AI labs, including OpenAI and Anthropic, to build more software for large industries. For startups, it also highlights concerns that major AI labs could launch competing features and displace smaller software makers. In this case, Orchestra is being absorbed into OpenAI rather than competing independently.